EPM

epm Therapeutics is a private U.S. biotechnology company developing fully synthetic cannabinoid acid derivative therapies for diseases with high unmet need. Its lead program, EPM301, is an orally administered cannabidiol acid methyl ester being advanced for multiple symptoms of Prader-Willi syndrome, particularly hyperphagia, with additional potential in sleep-wake and behavioral symptoms. The company was founded around intellectual property licensed from the Hebrew University of Jerusalem and research associated with Professor Raphael Mechoulam. EPM has reported Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. FDA for EPM301 in Prader-Willi syndrome, as well as EU orphan designation, and is working toward IND submission following a pre-IND interaction with FDA. Beyond EPM301, the company states it holds a broader patented portfolio of synthetic CBDA and CBG molecules for future development or partnering.